12:05 PM EDT, 05/08/2025 (MT Newswires) -- The European stock markets closed mixed in Thursday trading as the Stoxx Europe 600 rose 0.44%, Germany's DAX gained 1.01%, the FTSE 100 was off 0.32%, France's CAC 40 increased 0.89%, and the Swiss Market Index declined 0.43%.

The US announced a new trade deal with the UK on Thursday during a press conference in the Oval Office.

"The deal includes billions of dollars of increased market access for American exports, especially in agriculture, dramatically increasing access for American beef, ethanol and virtually all of the products produced by our great farmers," US President Donald Trump said Thursday.

Meanwhile, the UK said that US tariffs on steel and aluminum are "reduced to zero," Bloomberg reported Thursday, citing an emailed government statement. US tariffs on automobiles will be "immediately" cut from 27.5%, according to the report.

The European Union's European Commission has launched a public consultation regarding a list of US imports that might become subject to EU countermeasures if ongoing US-EU trade negotiations fail to produce satisfactory results, the Commission said Thursday.

The list includes a broad range of industrial and agricultural products from the US worth 95 billion euros ($107.33 billion), the Commission said, adding that is also consulting on potential restrictions on certain EU exports of steel scrap and chemical products to the US worth 4.4 billion euros.

And in corporate news, British pharmaceutical company GSK said Thursday that its phase 3 trial evaluating linerixibat as a potential treatment for cholestatic pruritus, or relentless itch, in primary biliary cholangitis patients met the primary and key secondary endpoints.

Shares of GSK declined 1.1% in London.

And biopharmaceutical company Argenx reported Q1 earnings Thursday of $2.58 per diluted share, swinging from a loss of $1.04 a year earlier. Analysts polled by FactSet expected EPS of $2.41. Operating income for the quarter ended March 31 was $807.4 million compared with $412.5 million a year earlier. Analysts surveyed by FactSet expected $817.6 million.

Shares of the biopharmaceutical company dropped more than 10% on the Brussels Stock Exchange.

http://www.mtnewswires.com
Copyright © 2025 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.